logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
REVB
Revelation Biosciences, Inc.
1.00
2 x 0.76
2 x 1.30
bid
ask
-
0.05
4.76%
2 @ 05:47 PM
1.03 +0.03 (2.71%)
Ytd-68.75%
1y-90.94%
1.00
day range
1.06
0.88
52 week range
11.60
Open1.06Prev Close1.05Low1.00High1.06Mkt Cap3.98M
Vol12.86KAvg Vol46.03KEPS27.03P/E0.04Forward P/E-0.13
Beta-0.15Short Ratio0.11Inst. Own8.90%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg1.06200-d Avg1.801yr Est12.75

REVB News

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#
benzinga.com
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN

– Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Comp

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
businesswire.com
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company
benzinga.com
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the a

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30,

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "
benzinga.com
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Marke

The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Ki

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
accessnewswire.com
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
accessnewswire.com
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C
benzinga.com
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic

Revelation Biosciences Announces Adoption of Stockholder Rights Plan
accessnewswire.com
Revelation Biosciences Announces Adoption of Stockholder Rights Plan

SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C

Revelation Biosciences Expands Acute Kidney Injury Advisory Board
accessnewswire.com
Revelation Biosciences Expands Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
accessnewswire.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co
benzinga.com
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
benzinga.com
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
accessnewswire.com
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C
benzinga.com
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conferenc

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
accessnewswire.com
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemin

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
accessnewswire.com
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
accessnewswire.com
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "

Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update
defenseworld.net
Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in shor
benzinga.com
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
accessnewswire.com
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended Decem

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (th
benzinga.com
Revelation Biosciences Files Prospectus For The Resale Of 4,272,500 Shares Via Warrants For Potentia

Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale,
benzinga.com
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf

How Do Investors Really Feel About Revelation Biosciences Inc?
benzinga.com
How Do Investors Really Feel About Revelation Biosciences Inc?
benzinga.com
Revelation Biosciences To Implement 1-For-4 Reverse Stock Split, January 28

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announce

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
accessnewswire.com
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:RE

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
Revelation Biosciences Enters Definitive Agreement For Immediate Exercise Of 13.065M Warrants At $0.

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
accessnewswire.com
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)
benzinga.com
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains

US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP ex

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
feeds.benzinga.com
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?

Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor

Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
benzinga.com
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?

Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
Revelation Biosciences Reaches Agreement With FDA On Approval Pathway For Gemini To Treat Acute Kidn

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
accessnewswire.com
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
accessnewswire.com
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
accessnewswire.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the
benzinga.com
Revelation Biosciences Starts GMP Production Of GEMINI, Placebo

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini,

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
Revelation Biosciences Announces Immediate Exercise Of 4.36M Warrants At $2.20/Share

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic